Carbogen for children with non-convulsive status epilepticus

Non-convulsive status epilepticus usually occurs in children with complex, severe epilepsies, and can lead to a significant loss of abilities. It needs to be treated promptly, however most existing therapies have sedative effects and increase the risk of complications such as chest infections.

Carbogen, a mixture of 95% oxygen and 5% carbon dioxide, is already used in the treatment of certain cancers, and studies have also shown that it is effective in stopping seizures in animals and adult humans. In this pilot study Dr Rob Forsyth from the University of Newcastle and colleagues aim to establish the safety, acceptability and effectiveness of Carbogen use in children with non-convulsive status epilepticus. Encouraging results from this study could lead to further studies on the effects of Carbogen in other types of seizure, and could represent a new direction for the acute treatment of seizures in the future.

Read more about this research into the use of carbogen for children with non-convulsive status epilepticus here.

To support our research you can donate online using the Donate today button below. To support a specific project please give the researcher’s name in the message box.

 

For other ways to donate see here.